Vimarsana
Biggest News Aggregation in the World

Page 16 - Webcast Today News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Webcast Today. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Webcast Today Today - Breaking & Trending Today

Harpoon presents updated interim clinical data for HPN424 at the 2021 ASCO Annual Meeting - Vimarsana News

Harpoon presents updated interim clinical data for HPN424 at the 2021 ASCO Annual Meeting

DJ Harpoon presents updated interim clinical data for HPN424 at the 2021 ASCO Annual Meeting Arix Bioscience PLC (ARIX) Harpoon presents updated interim clinical data for HPN424 at the 2021 ASCO

Capricor Therapeutics Reports First Quarter 2021 - Vimarsana News

Capricor Therapeutics Reports First Quarter 2021

Capricor Therapeutics Reports First Quarter 2021 Financial Results and Provides Corporate Update May 13, 2021 16:05 ET | Source: Capricor Therapeutics Capricor Therapeutics -- -Data for Phase II INSPIRE Clinical Trial Expected in Third Quarter- -Plan to File IND for Multivalent Exosome-mRNA Vaccine for SARS-CoV-2 in Third Quarter- -To Host Conference Call and Webcast Today at 4:30 p.m. ET- -- LOS ANGELES, May 13, 2021 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company focused on the development of transformative cell- and exosome-bas...

Amicus Therapeutics Announces First Quarter 2021 Financial Results and Corporate Updates - Vimarsana News

Amicus Therapeutics Announces First Quarter 2021 Financial Results and Corporate Updates

Published: May 10, 2021 Galafold® (migalastat) PerformanceReflects Continued Strong Adoption in All Key Global Regions; On-Track to Achieve Revenue Guidance of $300M-$315M 1Q21 Total Galafold Revenue of $66.4M Driven by Continued Global Growth Positive Pre-BLA Meeting Held with U.S. FDA for AT-GAA in Pompe Disease; Rolling BLA Submission On-Track for Completion in 2Q21with Global Submissions Expected Throughout 2021 New Data from Pompe and Fabry Gene Therapy Programs to be Presented at American Society of Gene & Cell Therapy 24th Annual Meeting May 11th-14th Continue to Strengthen Senior...

Ocugen Provides Business Update and First Quarter 2021 Financial Results - Vimarsana News

Ocugen Provides Business Update and First Quarter 2021 Financial Results

and Variant Neutralization Results — In April 2021, Ocugen announced that its co-development partner, Bharat Biotech International Limited ("Bharat Biotech"), shared positive results from the second interim analysis of its Phase 3 clinical trial of COVAXIN showing 78% overall efficacy against COVID-19 disease, 100% efficacy against severe COVID-19 disease (including hospitalization), and 70% efficacy against asymptomatic COVID-19 infection, indicating the potential to significantly reduce virus transmission. COVAXIN has additionally demonstrated a remarkable safety profile with several mil...

Neurocrine Biosciences Reports First Quarter 2021 Financial Results - Vimarsana News

Neurocrine Biosciences Reports First Quarter 2021 Financial Results

Neurocrine Biosciences Reports First Quarter 2021 Financial Results INGREZZA® (valbenazine) First Quarter 2021 Net Product Sales of $230 Million with Approximately 43,300 TRx Initiated Pediatric Phase III Registrational Program of Crinecerfont for the Treatment of Classic Congenital Adrenal Hyperplasia Initiated Phase II Study of NBI-827104 in Essential Tremor News provided by Share this article Share this article SAN DIEGO, May 5, 2021 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced its financial results for the first quarter ended March 31, 2021 and provided re...